OBJECTIVE: This study evaluates the risk of developing psoriatic arthritis in patients treated with IL-23 inhibitors compared to IL-12/23 inhibitors.
METHODS: This retrospective cohort study utilized data from the TriNetX, including adult patients diagnosed with PsO. Patients with IL-23 or IL-12/23 inhibitors treatment were included and propensity score matched. The primary outcome was the incidence of psoriatic arthritis (PsA), analyzed using a Cox regression hazard model and Kaplan-Meier estimates.
RESULTS: The study included matched cohorts of patients treated with IL-23 inhibitors (n = 2273) and IL-12/23 inhibitors (n = 2995). Cox regression analysis revealed no significant difference in the cumulative incidence of PsA between the IL-23i and IL-12/23i cohorts (P = .812). Kaplan-Meier estimates confirmed similar cumulative incidences of arthropathic PsO in both cohorts over the study period.
CONCLUSIONS: Long-term follow-up studies are required to understand more of the effects of these interleukin inhibitors.
CONCLUSIONS: No significant difference but a numerically lower risk of psoriatic arthritis in PsO patients treated with IL-23 inhibitors than with IL-12/23 inhibitors was found, underscoring their comparable efficacy in PsO management and follow-up.
目的:本研究评估了与IL-12/23抑制剂相比,使用IL23抑制剂治疗的患者发生银屑病关节炎的风险。
方法:这项回顾性队列研究利用了TriNetX的数据,包括被诊断为牛皮癣的成年患者。包括使用IL-23或IL-12/23抑制剂治疗的患者并且倾向评分匹配。主要结果是关节性银屑病的发病率,使用Cox回归风险模型和Kaplan-Meier估计进行分析。
结果:该研究包括使用IL-23抑制剂(n=2,273)和IL-12/23抑制剂(n=2,995)治疗的患者的配对队列。Cox回归分析显示,IL-23i和IL-12/23i队列之间的关节性银屑病累积发生率没有显着差异(p=0.812)。Kaplan-Meier估计证实,在研究期间,两个队列中关节炎性银屑病的累积发病率相似。
结论:需要长期随访研究来了解更多这些白介素抑制剂的作用。
结论:在使用IL-23抑制剂治疗的PsO患者中,与使用IL-12/23抑制剂相比,PsA的风险没有显着差异,但在数值上更低。强调了它们在PsO管理和随访中的可比疗效。